METHOD FOR DIAGNOSING RESPONSIVENESS OF THERAPEUTIC AGENT FOR SECOND LINE TREATMENT OF CANCER PATIENT USING CIRCULATING TUMOR CELLS
The present invention relates to a method for diagnosing the responsiveness of a therapeutic agent for a second line treatment of a cancer patient using circulating tumor cells. More specifically, the present invention relates to a method for calculating a predicted value of treatment responsiveness...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KIM, JINJU CHUNG, KYUNG SOOK KIM, SUNG SU CHO, SANG REA BYUN, BO HYUN CHOI, JOON-SEOK SHIN, YOUNG KEE OH, MYUNG RYURL |
| description | The present invention relates to a method for diagnosing the responsiveness of a therapeutic agent for a second line treatment of a cancer patient using circulating tumor cells. More specifically, the present invention relates to a method for calculating a predicted value of treatment responsiveness which comprises several steps of separating and detecting CTC from a blood sample of a patient to provide information for determination of the second line treatment through detection of gene mutation information in the cancer patient, the method being suitable for automation. The method of the present invention can be useful for the purpose of guiding future treatment, including determination of the need for administering an anti-cancer therapeutic agent, since it is possible to predict and diagnose the responsiveness of a patient to the therapeutic agent by calculating the predicted value of treatment responsiveness using the blood of a patient who is subject to the second line treatment and from whom obtaining an FFPE tissue sample is difficult.
La présente invention concerne une méthode permettant de diagnostiquer la sensibilité à un agent thérapeutique pour un traitement de deuxième intention d'un patient cancéreux à l'aide de cellules tumorales circulantes. Plus précisément, la présente invention concerne une méthode pour calculer une valeur prédite de sensibilité à un traitement qui comprend plusieurs étapes de séparation et de détection des CTC à partir d'un échantillon de sang d'un patient afin de fournir des informations pour la détermination du traitement de deuxième intention par l'intermédiaire de la détection d'informations d'une mutation génique chez le patient cancéreux, le procédé convenant pour une automatisation. La méthode de la présente invention peut être utile à des fins d'orientation d'un traitement futur, comprenant la détermination de la nécessité de l'administration d'un agent thérapeutique anticancéreux, étant donné qu'il est possible de prédire et de diagnostiquer la sensibilité d'un patient à l'agent thérapeutique par le calcul de la valeur prédite de sensibilité à un traitement à l'aide du sang d'un patient qui est soumis au traitement de deuxième intention et à partir duquel l'obtention d'un échantillon de tissu FFPE est difficile.
본 발명은 순환 종양 세포를 이용한 암 환자의 2차 치료용 치료제 반옹성 진단 방법에 관한 것으로, 보다 상세하게는 암 환자의 유전자 변이 정보 검출을 통한 2차 치료 (second l ine treatment ) 판단을 위한 정보를 제공하기 위하여， 환자의 혈액 시료로부터 CTC를 분리하여 검출하는 여러 단계를 포함하는 치료 반응성 예측치를 산출하는 방법으로 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2016018115A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2016018115A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2016018115A13</originalsourceid><addsrcrecordid>eNqNjEEKwjAURLtxIeodPrgWGkVxG35_20CalORHl6VIXIkW6g28uGnxAK5mmJk3y-zTENe2gNI6KJSsjPXKVODIt9Z4dSFD3oMtgWtysqXACkFWZHhGPKE1BWhlCNiR5GZq0hylQXLQSlZTEuZXVA6DTlHyHJrEI2nt19ni3j_GuPnpKtuWxFjv4vDq4jj0t_iM7-5q97k45eIsxFGKw3-rLz7GPho</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHOD FOR DIAGNOSING RESPONSIVENESS OF THERAPEUTIC AGENT FOR SECOND LINE TREATMENT OF CANCER PATIENT USING CIRCULATING TUMOR CELLS</title><source>esp@cenet</source><creator>KIM, JINJU ; CHUNG, KYUNG SOOK ; KIM, SUNG SU ; CHO, SANG REA ; BYUN, BO HYUN ; CHOI, JOON-SEOK ; SHIN, YOUNG KEE ; OH, MYUNG RYURL</creator><creatorcontrib>KIM, JINJU ; CHUNG, KYUNG SOOK ; KIM, SUNG SU ; CHO, SANG REA ; BYUN, BO HYUN ; CHOI, JOON-SEOK ; SHIN, YOUNG KEE ; OH, MYUNG RYURL</creatorcontrib><description>The present invention relates to a method for diagnosing the responsiveness of a therapeutic agent for a second line treatment of a cancer patient using circulating tumor cells. More specifically, the present invention relates to a method for calculating a predicted value of treatment responsiveness which comprises several steps of separating and detecting CTC from a blood sample of a patient to provide information for determination of the second line treatment through detection of gene mutation information in the cancer patient, the method being suitable for automation. The method of the present invention can be useful for the purpose of guiding future treatment, including determination of the need for administering an anti-cancer therapeutic agent, since it is possible to predict and diagnose the responsiveness of a patient to the therapeutic agent by calculating the predicted value of treatment responsiveness using the blood of a patient who is subject to the second line treatment and from whom obtaining an FFPE tissue sample is difficult.
La présente invention concerne une méthode permettant de diagnostiquer la sensibilité à un agent thérapeutique pour un traitement de deuxième intention d'un patient cancéreux à l'aide de cellules tumorales circulantes. Plus précisément, la présente invention concerne une méthode pour calculer une valeur prédite de sensibilité à un traitement qui comprend plusieurs étapes de séparation et de détection des CTC à partir d'un échantillon de sang d'un patient afin de fournir des informations pour la détermination du traitement de deuxième intention par l'intermédiaire de la détection d'informations d'une mutation génique chez le patient cancéreux, le procédé convenant pour une automatisation. La méthode de la présente invention peut être utile à des fins d'orientation d'un traitement futur, comprenant la détermination de la nécessité de l'administration d'un agent thérapeutique anticancéreux, étant donné qu'il est possible de prédire et de diagnostiquer la sensibilité d'un patient à l'agent thérapeutique par le calcul de la valeur prédite de sensibilité à un traitement à l'aide du sang d'un patient qui est soumis au traitement de deuxième intention et à partir duquel l'obtention d'un échantillon de tissu FFPE est difficile.
본 발명은 순환 종양 세포를 이용한 암 환자의 2차 치료용 치료제 반옹성 진단 방법에 관한 것으로, 보다 상세하게는 암 환자의 유전자 변이 정보 검출을 통한 2차 치료 (second l ine treatment ) 판단을 위한 정보를 제공하기 위하여， 환자의 혈액 시료로부터 CTC를 분리하여 검출하는 여러 단계를 포함하는 치료 반응성 예측치를 산출하는 방법으로 자동화에 적합한 방법에 관한 것이다. 본 발명의 방법은 FFPE 조직 시료를 얻기 어려운 2차 치료 대상의 환자의 혈액을 이용하여 치료 반응성 예측치를 산출하여， 환자의 치료제에 대한 반응성 예측， 진단이 가능하므로 항암치료제의 투여 필요성 판단을 비롯하여 향후 치료의 방향에 대한 단서를 제시하는 목적으로 유용하게 사용할 수 있다.</description><language>eng ; fre ; kor</language><subject>APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY ; BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160204&DB=EPODOC&CC=WO&NR=2016018115A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160204&DB=EPODOC&CC=WO&NR=2016018115A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KIM, JINJU</creatorcontrib><creatorcontrib>CHUNG, KYUNG SOOK</creatorcontrib><creatorcontrib>KIM, SUNG SU</creatorcontrib><creatorcontrib>CHO, SANG REA</creatorcontrib><creatorcontrib>BYUN, BO HYUN</creatorcontrib><creatorcontrib>CHOI, JOON-SEOK</creatorcontrib><creatorcontrib>SHIN, YOUNG KEE</creatorcontrib><creatorcontrib>OH, MYUNG RYURL</creatorcontrib><title>METHOD FOR DIAGNOSING RESPONSIVENESS OF THERAPEUTIC AGENT FOR SECOND LINE TREATMENT OF CANCER PATIENT USING CIRCULATING TUMOR CELLS</title><description>The present invention relates to a method for diagnosing the responsiveness of a therapeutic agent for a second line treatment of a cancer patient using circulating tumor cells. More specifically, the present invention relates to a method for calculating a predicted value of treatment responsiveness which comprises several steps of separating and detecting CTC from a blood sample of a patient to provide information for determination of the second line treatment through detection of gene mutation information in the cancer patient, the method being suitable for automation. The method of the present invention can be useful for the purpose of guiding future treatment, including determination of the need for administering an anti-cancer therapeutic agent, since it is possible to predict and diagnose the responsiveness of a patient to the therapeutic agent by calculating the predicted value of treatment responsiveness using the blood of a patient who is subject to the second line treatment and from whom obtaining an FFPE tissue sample is difficult.
La présente invention concerne une méthode permettant de diagnostiquer la sensibilité à un agent thérapeutique pour un traitement de deuxième intention d'un patient cancéreux à l'aide de cellules tumorales circulantes. Plus précisément, la présente invention concerne une méthode pour calculer une valeur prédite de sensibilité à un traitement qui comprend plusieurs étapes de séparation et de détection des CTC à partir d'un échantillon de sang d'un patient afin de fournir des informations pour la détermination du traitement de deuxième intention par l'intermédiaire de la détection d'informations d'une mutation génique chez le patient cancéreux, le procédé convenant pour une automatisation. La méthode de la présente invention peut être utile à des fins d'orientation d'un traitement futur, comprenant la détermination de la nécessité de l'administration d'un agent thérapeutique anticancéreux, étant donné qu'il est possible de prédire et de diagnostiquer la sensibilité d'un patient à l'agent thérapeutique par le calcul de la valeur prédite de sensibilité à un traitement à l'aide du sang d'un patient qui est soumis au traitement de deuxième intention et à partir duquel l'obtention d'un échantillon de tissu FFPE est difficile.
본 발명은 순환 종양 세포를 이용한 암 환자의 2차 치료용 치료제 반옹성 진단 방법에 관한 것으로, 보다 상세하게는 암 환자의 유전자 변이 정보 검출을 통한 2차 치료 (second l ine treatment ) 판단을 위한 정보를 제공하기 위하여， 환자의 혈액 시료로부터 CTC를 분리하여 검출하는 여러 단계를 포함하는 치료 반응성 예측치를 산출하는 방법으로 자동화에 적합한 방법에 관한 것이다. 본 발명의 방법은 FFPE 조직 시료를 얻기 어려운 2차 치료 대상의 환자의 혈액을 이용하여 치료 반응성 예측치를 산출하여， 환자의 치료제에 대한 반응성 예측， 진단이 가능하므로 항암치료제의 투여 필요성 판단을 비롯하여 향후 치료의 방향에 대한 단서를 제시하는 목적으로 유용하게 사용할 수 있다.</description><subject>APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY</subject><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjEEKwjAURLtxIeodPrgWGkVxG35_20CalORHl6VIXIkW6g28uGnxAK5mmJk3y-zTENe2gNI6KJSsjPXKVODIt9Z4dSFD3oMtgWtysqXACkFWZHhGPKE1BWhlCNiR5GZq0hylQXLQSlZTEuZXVA6DTlHyHJrEI2nt19ni3j_GuPnpKtuWxFjv4vDq4jj0t_iM7-5q97k45eIsxFGKw3-rLz7GPho</recordid><startdate>20160204</startdate><enddate>20160204</enddate><creator>KIM, JINJU</creator><creator>CHUNG, KYUNG SOOK</creator><creator>KIM, SUNG SU</creator><creator>CHO, SANG REA</creator><creator>BYUN, BO HYUN</creator><creator>CHOI, JOON-SEOK</creator><creator>SHIN, YOUNG KEE</creator><creator>OH, MYUNG RYURL</creator><scope>EVB</scope></search><sort><creationdate>20160204</creationdate><title>METHOD FOR DIAGNOSING RESPONSIVENESS OF THERAPEUTIC AGENT FOR SECOND LINE TREATMENT OF CANCER PATIENT USING CIRCULATING TUMOR CELLS</title><author>KIM, JINJU ; CHUNG, KYUNG SOOK ; KIM, SUNG SU ; CHO, SANG REA ; BYUN, BO HYUN ; CHOI, JOON-SEOK ; SHIN, YOUNG KEE ; OH, MYUNG RYURL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2016018115A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; kor</language><creationdate>2016</creationdate><topic>APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY</topic><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KIM, JINJU</creatorcontrib><creatorcontrib>CHUNG, KYUNG SOOK</creatorcontrib><creatorcontrib>KIM, SUNG SU</creatorcontrib><creatorcontrib>CHO, SANG REA</creatorcontrib><creatorcontrib>BYUN, BO HYUN</creatorcontrib><creatorcontrib>CHOI, JOON-SEOK</creatorcontrib><creatorcontrib>SHIN, YOUNG KEE</creatorcontrib><creatorcontrib>OH, MYUNG RYURL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KIM, JINJU</au><au>CHUNG, KYUNG SOOK</au><au>KIM, SUNG SU</au><au>CHO, SANG REA</au><au>BYUN, BO HYUN</au><au>CHOI, JOON-SEOK</au><au>SHIN, YOUNG KEE</au><au>OH, MYUNG RYURL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHOD FOR DIAGNOSING RESPONSIVENESS OF THERAPEUTIC AGENT FOR SECOND LINE TREATMENT OF CANCER PATIENT USING CIRCULATING TUMOR CELLS</title><date>2016-02-04</date><risdate>2016</risdate><abstract>The present invention relates to a method for diagnosing the responsiveness of a therapeutic agent for a second line treatment of a cancer patient using circulating tumor cells. More specifically, the present invention relates to a method for calculating a predicted value of treatment responsiveness which comprises several steps of separating and detecting CTC from a blood sample of a patient to provide information for determination of the second line treatment through detection of gene mutation information in the cancer patient, the method being suitable for automation. The method of the present invention can be useful for the purpose of guiding future treatment, including determination of the need for administering an anti-cancer therapeutic agent, since it is possible to predict and diagnose the responsiveness of a patient to the therapeutic agent by calculating the predicted value of treatment responsiveness using the blood of a patient who is subject to the second line treatment and from whom obtaining an FFPE tissue sample is difficult.
La présente invention concerne une méthode permettant de diagnostiquer la sensibilité à un agent thérapeutique pour un traitement de deuxième intention d'un patient cancéreux à l'aide de cellules tumorales circulantes. Plus précisément, la présente invention concerne une méthode pour calculer une valeur prédite de sensibilité à un traitement qui comprend plusieurs étapes de séparation et de détection des CTC à partir d'un échantillon de sang d'un patient afin de fournir des informations pour la détermination du traitement de deuxième intention par l'intermédiaire de la détection d'informations d'une mutation génique chez le patient cancéreux, le procédé convenant pour une automatisation. La méthode de la présente invention peut être utile à des fins d'orientation d'un traitement futur, comprenant la détermination de la nécessité de l'administration d'un agent thérapeutique anticancéreux, étant donné qu'il est possible de prédire et de diagnostiquer la sensibilité d'un patient à l'agent thérapeutique par le calcul de la valeur prédite de sensibilité à un traitement à l'aide du sang d'un patient qui est soumis au traitement de deuxième intention et à partir duquel l'obtention d'un échantillon de tissu FFPE est difficile.
본 발명은 순환 종양 세포를 이용한 암 환자의 2차 치료용 치료제 반옹성 진단 방법에 관한 것으로, 보다 상세하게는 암 환자의 유전자 변이 정보 검출을 통한 2차 치료 (second l ine treatment ) 판단을 위한 정보를 제공하기 위하여， 환자의 혈액 시료로부터 CTC를 분리하여 검출하는 여러 단계를 포함하는 치료 반응성 예측치를 산출하는 방법으로 자동화에 적합한 방법에 관한 것이다. 본 발명의 방법은 FFPE 조직 시료를 얻기 어려운 2차 치료 대상의 환자의 혈액을 이용하여 치료 반응성 예측치를 산출하여， 환자의 치료제에 대한 반응성 예측， 진단이 가능하므로 항암치료제의 투여 필요성 판단을 비롯하여 향후 치료의 방향에 대한 단서를 제시하는 목적으로 유용하게 사용할 수 있다.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; kor |
| recordid | cdi_epo_espacenet_WO2016018115A1 |
| source | esp@cenet |
| subjects | APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | METHOD FOR DIAGNOSING RESPONSIVENESS OF THERAPEUTIC AGENT FOR SECOND LINE TREATMENT OF CANCER PATIENT USING CIRCULATING TUMOR CELLS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T10%3A53%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KIM,%20JINJU&rft.date=2016-02-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2016018115A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |